Company Profile

Astek Diagnostics LLC
Profile last edited on: 8/9/2023      CAGE: 8QMK0      UEI: DWMKQ81LJLW1

Business Identifier: Platform (Eugris) guiding physician's prescription of appropriate antibiotics for patients.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

875 Hollins Street Suite 201
Baltimore, MD 21227
   (484) 459-8258
Location: Single
Congr. District: 03
County: Baltimore

Public Profile

A medical device company commercializing a novel technology for detecting bacterial infections in blood, Astek Diagnostics is addressing the problem of inappropriate use of antibiotics: too little or too much. The firm's website notes that the life-threatening Sepsis is a life-threatening condition annually involving more than 1 million US-based patients -- and even more worldwide -- making this one condition a leading causes of death. For those suspected of sepsis/septic shock, rapid initiation of correct antibiotic therapy is crucial: over 270,000 people die each year due to sepsis. Astek Diagnnostic's benchtop diagnostic device employs a single-use cartridge capable (in about one hour) of identification of bacterial infection in the blood antibiotic sensitivity. The firm's first product - EugrisTM, is a benchtop analyzer that - in that one hour - can identify presence of bacterial infection in blood and can perform antibiotic susceptibility testing (AST) of the bacterium. Result: in very short order, physicians are imformed which antibiotics would best be given to patients.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NSF $255,975
Project Title: Rapid detection of blood-borne bacteria and determination of antibiotic resistance
0 1 NSF $274,587
Project Title: Automated One-Hour Testing for Bacteremia and Antibiotic Sensitivity

Key People / Management

  Mustafa Al-Adhami -- CEO

  Ashlee Brennan

  Courtney Cavin

  Rick Faint

  Alastair Mackay

  Ted Olsen

  Kevin Tran -- CTO

Company News

There are no news available.